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http:WHAT THIS PAPER ADDS
The treatment of carotid stenosis is one of the best studied disease processes in vascular surgery, and several
societies have published guidelines and recommendations about the indications for CEA and CAS. However,
considerable variation exists between countries and centres. In this study, variation in the treatment patterns in
over 400 centres in the United States, Europe, Australia, and New Zealand are analysed. The main focus is on
indications and the proportion of stenting. Furthermore, an analysis on the influence of the reimbursement
system on indications was performed.Objectives: The aim was to determine current practice for the treatment of carotid stenosis among 12 countries
participating in the International Consortium of Vascular Registries (ICVR).
Methods: Data from the United States Vascular Quality Initiative (VQI) and the Vascunet registry collaboration
(including 10 registries in Europe and Australasia) were used. Variation in treatment modality of asymptomatic
versus symptomatic patients was analysed between countries and among centres within each country.
Results: Among 58,607 procedures, octogenarians represented 18% of all patients, ranging from 8% (Hungary) to
22% (New Zealand and Australia). Women represented 36%, ranging from 29% (Switzerland) to 40% (USA). The
proportion of carotid artery stenting (CAS) among asymptomatic patients ranged from 0% (Finland) to 26% (Sweden)
and among symptomatic patients from 0% (Denmark) to 19% (USA). Variation among centres within countries for
CAS was highest in the United States and Australia (from 0% to 80%). The overall proportion of asymptomatic
patients was 48%, but varied from 0% (Denmark) to 73% (Italy). There was also substantial centre level variation
within each country in the proportion of asymptomatic patients, most pronounced in Australia (0e72%), Hungary
(5e55%), and the United States (0e100%). Countries with fee for service reimbursement had higher rates of
treatment in asymptomatic patients than countries with population based reimbursement (OR 5.8, 95% CI 4.4e7.7).
Conclusions: Despite evidence about treatment options for carotid artery disease, the proportion of
asymptomatic patients, treatment modality, and the proportion of women and octogenarians vary considerably
among and within countries. There was a significant association of treating more asymptomatic patients in
countries with fee for service reimbursement. The findings reflect the inconsistency of the existing guidelines and
a need for cooperation among guideline committees all over the world.
 2017 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Table 1. The capture rate of the registers in the participating
countries (comparison of number of procedures registered in the
registry compared with the procedures registered in the official










Australia 70% 37% 8025
Denmark > 95% > 95% 1519
Finland a 40% (100%) 40% (100%) 938
Hungary 80% 60% 5388
Iceland 100% 100% 78
Italy 70% 40e50% 6937
Norway 80% 80% 1033
Sweden > 98% > 90% 4047
Switzerland b 50% < 10% 1811
New Zealand 85% < 5% 1478
USA c 15% (100%) 15% (100%) 27,353
AAA ¼ abdominal aortic aneurysm; CAS ¼ carotid artery stenting;
CEA ¼ carotid endarterectomy.
a In Finland the registry is regional and covers 100% of the pro-
cedures in the regions, audited using hospital records.
b The Swiss vascular registry includes patients undergoing surgery
for AAA in public hospitals, and captures 85% of all open and 70%
of all endovascular procedures in the country.
c US data represent an estimated 15% of all CEA and CAS pro-
cedures over the study period. All participating centres capture
100% of their consecutive cases, audited using billing data.
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Carotid artery disease has long been associated with
ischaemic stroke. In the early 1990s, large randomised trials
clarified the indications for carotid endarterectomy (CEA)
treatment of symptomatic disease. Surgical intervention in
patients with carotid artery stenosis of  50% in the
presence of symptoms was found to be highly beneficial,
provided that the complication rates were low.1,2 Indeed,
the absolute risk reduction of CEA compared with best
medical treatment (BMT) in patients with 50e69% and 70e
99% symptomatic carotid stenosis was shown to be 7.8%
and 15.6% respectively.3,4 Carotid artery stenting (CAS) as a
treatment modality for carotid stenosis has also been
studied and compared with CEA. In a recent pooled analysis
of 3433 randomised patients, CEA was safer in the short
term than CAS because of the increased risk of stroke in CAS
patients over the age of 70 years, although no difference
was apparent in younger patients.5
Treatment of asymptomatic carotid stenosis is more
controversial. In two large randomised trials with more than
4700 patients with asymptomatic carotid stenosis, the ab-
solute risk reduction of stroke when CEA was compared
with BMT was 5.3e5.9% after 5 years.6,7 Furthermore, in
the 10 years since these trials, BMT has improved to the
point where the annual stroke risk from asymptomatic
stenosis is now estimated by some to be as low as 0.5%.8
Current guidelines regarding asymptomatic patients
recommend careful patient selection, primarily offering CEA
or CAS to those under 75 years of age9 or those with life
expectancy more than 5 years.10,11
Despite several randomised controlled trials (RCTs) being
available, there are still differences between medical society
guidelines regarding the treatment of carotid stenosis.12
Registries provide a real world view and can demonstrate
variation in how practice guidelines are translated into
clinical practice.13 Registries also permit analysis of varia-
tion among different geographical regions and among
centres. In a previous study, variation has been shown to
exist between European countries, New Zealand, and
Australia,14 but no centre level analysis has been
performed.
The present study included data from 11 countries on
three continents: Australasia, Europe, and North America.
Variations in treatment of carotid artery stenosis were
examined over a 4 year period (2010e2013). Trends were
analysed in the treatment of asymptomatic versus symp-
tomatic carotid stenosis and the distribution of treatment
modality (CEA vs. CAS) for each patient group, focusing on
variation among countries and among centres within
countries. Data were analysed for difference in treatment
among octogenarians and by gender. In asymptomatic pa-
tients the association of treatment and fee for service
versus population based reimbursement was analysed. The
authors sought to describe how actual practice compares
with society guidelines in an international cohort of
patients.MATERIALS AND METHODS
To achieve these objectives, the International Consortium of
Vascular Registries (ICVR, www.icvr-initative.org) was
formed in 2014 as a collaboration of the US Food and Drug
Administration Medical Device Epidemiology Network
(MDEpiNet) Science and Infrastructure Centre at Cornell
University and 11 vascular registries from Australasia,
Europe, and North America. This represents a collaboration
of national registries in VASCUNET, based on the European
Society for Vascular Surgery, and the Vascular Quality
Initiative (VQI), based on the Society for Vascular Surgery.
Registries contributing data to this ICVR project are from
Australia, Denmark, Finland, Hungary, Iceland, Italy, New
Zealand, Norway, Sweden, Switzerland, and the United
States. De-identified individual patient data from 10 na-
tional registries and aggregated patient data from Italy were
submitted to the Cornell Analytic Centre for analysis.
In six of the participating countries, registry is national,
covering all hospitals in the country (Australia, Denmark,
Hungary, Iceland, New Zealand, Norway, and Sweden). The
Finnish registry captured all treatment from three hospital
regions (Helsinki, South Savonia, and South Karelia). Italy
and the United States captured all data from selected
centres in voluntary national registries. Switzerland
captured all procedures performed within their public but
not private healthcare sector. Thus, data that are presented
represent 15e100% of all procedures performed in the
countries surveyed (Table 1). The percentage of CAS pro-
cedures enrolled was lower than CEA procedures because in
Carotid Stenosis Treatment 513many countries CAS is performed by specialists other than
vascular surgeons who don’t always participate in these
registries.
Patients undergoing CEA or CAS from January 1, 2010, to
December 31, 2013, were included for all countries except
Italy, which submitted data for 2012e2013. A dataset was
created on the basis of common variables across the regis-
tries, including country, de-identified hospital number, pa-
tient’s age, gender, and risk factors (diabetes, cardiac disease,
stroke history, pulmonary disease, hypertension), indication
for surgery (symptomatic vs. asymptomatic), type of the
procedure (CAS or CEA), and year of the procedure.The grade
of stenosis was categorized by the criteria of each centre as a
percentage of the diameter of stenosis compared with the
distal internal carotid artery (ICA) (NASCET), except in Italy,
where there is a variation between the hospitals (some
centres use NASCET, other centres ECST).
For analyses comparing the proportion of CAS versus CEA
used to treat carotid stenosis, only those centres entering
data for both CAS and CEA were included (all centres
contributing data were included in separate CEA and CAS
analyses). Italy and Norway were excluded from centre level
analysis because centre level information was not available.Description of regions and centres
Variation across countries and among centres within
countries was analysed. Because of its large size and
number of participating centres, the United States was
further divided into five regions (New England, East, South,
Midwest, and West) for comparison. Eleven countries and
418 centres were included in the analyses. In the analysis ofTable 2. Characteristics of patients undergoing carotid procedures.
Asymptomatic
CEA (n ¼ 24952) CAS (n ¼ 3135)
Year
2010 2844 (11.4%) 261 (8.3%)
2011 3713 (14.9%) 416 (13.3%)
2012 7901 (31.7%) 1071 (34.2%)
2013 10,494(42.1%) 1387 (44.2%)
Age
65þ 18,983 (76.1%) 2386 (76.1%)
80þ 3987 (16.0%) 561 (17.9%)
Gender
Female 9372 (37.6%) 1061 (33.8%)
Male 15,571 (62.4%) 2074 (66.2%)
Comorbidities
Diabetes 8018 (32.2%) 1031 (33.1%)
Cardiac 9323 (37.4%) 1372 (44.1%)
Pulmonary 3421 (18.9%) 423 (20.2%)
Stroke 101 (0.7%) 223 (12.2%)
Hypertension 21,781 (87.4%) 2745 (88.1%)
Stenosis  70% 22,615 (95.2%) 2924 (94.3%)
General anaesthesia 20,025 (83.1%) 296 (10.1%)
Note. Missing data: 0.7% of diabetes, 0.8% of cardiac history, 29.1% of
stenosis grade, 13.9% of anaesthesia. CAS ¼ carotid artery stenting; Ctime trends, only those centres that submitted data for all 4
years (2010e2013) were included. Countries were also
grouped and analysed by whether they primarily use fee for
service or population based reimbursement for these pro-
cedures. In countries that have largely fee for service
reimbursement, physician payment is proportional to the
number of procedures performed, and in countries with
population based reimbursement, physician payment is in-
dependent of the number of procedures performed.Statistical methods
Variations in symptom status and patient age, gender, and
carotid stenosis severity were first identified within the
entire cohort at the country and centre level and repre-
sented graphically. Data are presented as percentages and
95% confidence intervals (CI). Small centres (with number
of procedures < 10) were excluded when describing centre
level variation due to unstable estimates. After excluding
the centres that were not participating in both CAS and CEA
modules, the proportion of CAS procedures relative to CEA
was examined across countries among both asymptomatic
and symptomatic patients. Differences in patient charac-
teristics and use of CAS were compared between symp-
tomatic and asymptomatic patients and across countries
with chi-square tests. Trends in indication, patient de-
mographics, and use of CAS were analysed over time. The
CochraneArmitage test for trend was used to assess the
significance. Comparison between countries using fee for
service and population based reimbursement methods
were made to assess compliance with guidelines. Pro-
portions of asymptomatic patients treated and proportionSymptomatic
p CEA (n ¼ 27482) CAS (n ¼ 3038) p
< .01 < .01
5167 (18.8%) 308 (10.1%)
5796 (21.1%) 449 (14.8%)
7699 (28.0%) 1005 (33.1%)
8820 (32.1%) 1276 (42.0%)
.98 20,447 (74.4%) 2096 (69.0%) < .01
< .01 5295 (19.3%) 550 (18.1%) .12
< .01 .02
9475 (34.5%) 1111 (36.6%)
17,992 (65.5%) 1927 (63.4%)
.29 7385 (27.2%) 999 (33.1%) < .01
< .01 10,093 (37.2%) 1255 (41.8%) < .01
.15 3161 (16.5%) 555 (25.3%) < .01
< .01 5353 (50.9%) 758 (52.7%) .20
.25 23,125 (85.1%) 2566 (85.1%) .95
.03 20,241 (87.8%) 2692 (91.1%) < .01
< .01 17,739 (79.4%) 343 (12.3%) <0 .01
pulmonary history, 48.7% of stroke, 0.8% of hypertension, 12.1% of
EA ¼ carotid endarterectomy.
514 M. Venermo et al.of patients over 75 years old among asymptomatic patients
were compared. A generalised linear model, accounting for
country and centre clustering, was used to evaluate the
difference between the two groups of countries. Patients
with missing values for a specific characteristic were
excluded for analysis of that part. Statistical analyses were
performed using SAS v9.3 (SAS Institute Inc., Cary, NC, USA)
and Microsoft Excel 2013.RESULTS
There were 58,607 procedures conducted for carotid ste-
nosis; the majority (89.5%) were CEA (n ¼ 52,434) with only
10.5% CAS (n ¼ 6173). Patients were predominantly male
(64%), and 75% were over 65 years of age. The indication
for treatment was asymptomatic stenosis in 48% andFigure 1. The proportion of asymptomatic patients in 11 participant csymptomatic stenosis in 52%. The majority of patients (92%)
had  70% stenosis of the ICA. Baseline characteristics of
the patients are presented in Table 2.Risk factors
The most common risk factor among all patients treated for
carotid stenosis was hypertension, with a prevalence of 63% in
Norway and 92% in Hungary. The prevalence of cardiac risk
factors was highest in Australia (52%) and lowest in the
Denmark (24%). The proportion of diabetic patients was
highest in the United States (35%) and lowest in Iceland (15%).
The prevalence of pulmonary disease was only 9% in
Switzerland but as high as 21% in the United States. Risk fac-
tors among asymptomatic patients and symptomatic patients
were similar (Supplementary material, Tables S1 and S2).ountries (A) and in the participating hospitals in each country (B).
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symptomatic patients
The percentage of asymptomatic patients varied between
0.0% in Denmark and 73% in Italy (Fig. 1A). The majority of
the procedures in the United States were performed on
asymptomatic patients (60.1%), with minor variation among
its five regions (Fig. 1A). In Australia, the proportion of
asymptomatic patients was lower at 30%. The lowest pro-
portion of asymptomatic patients was reported from the
Nordic countries, varying between 0.0% in Denmark and
16% in Norway. The proportion of severe (> 70%) stenosis
among asymptomatic patients was 94.3% and varied from
93.8% in USA to 100% in Iceland.
The variation in the percentage of asymptomatic patients
between hospitals in most countries was as large as the
variation between countries. The largest national variation
was noted in the United States, with the proportion of
asymptomatic patients varying from 0% to 100% among
centres, followed by Australia from 0% to 72% and Hungary
from 5% to 55%. In Denmark, there was no variation noted,
as all treated patients were symptomatic. The variation in
indication between the hospitals in each country is pre-
sented in Fig. 1B.
There was no overall trend noted with regard to the
proportion of symptomatic patients treated between 2010
and 2013. Interestingly, a significant trend was seen in two
countries: in Sweden the proportion of symptomatic pa-
tients increased from 81% in 2010 to 90% in 2013 (p < .01).
In Hungary, in contrast, the proportion of symptomatic
patients decreased from 61% in 2010 to 56% in 2013
(p < .01).
Treatment of asymptomatic patients
The majority of asymptomatic patients were treated by CEA
(88%) and a minority were treated by CAS (12%). The pro-
portion of asymptomatic patients treated by CAS varied
from 0% in Finland and Iceland to 26% in Sweden (Fig. 2).
The proportion of CAS procedures in asymptomatic patientsFigure 2. The proportion of carotid artery stenting for all procedures i
countries. Note. New Zealand and Norway were excluded from the ana
the registry.in the United States was 12%, with little variation across
regions. Variation between centres was highest in the
United States (0e80%), followed by Australia (0e70%),
whereas in Iceland and Finland none of the centres per-
formed CAS in asymptomatic patients (Fig. 3A).
Octogenarians made up 16% of individuals treated for
asymptomatic stenosis. Among all asymptomatic patients
undergoing CAS, 18% were octogenarians, with variation
between countries noted from 0% in Norway to 23% in Italy.
Among asymptomatic patients undergoing CEA, 16% were
octogenarians with variation among countries and regions
being from 0% in Finland to 20% in Italy (Supplementary
Material Fig. S1). Thus, CAS was performed as often in oc-
togenarians as in younger patients (13% vs. 12%, p ¼ .23).
Women constituted 37% of all asymptomatic patients.
The percentage of women treated for asymptomatic carotid
stenosis varied among the countries, from 12% in Finland to
41% in the United States (Supplementary Material Fig. S2).
The percentage of women treated was similar for CAS (34%)
and CEA (38%) procedures.Treatment of asymptomatic stenosis and reimbursement
system
In countries with fee for service reimbursement (Australia,
Italy, Switzerland, United States), 56% of all carotid proced-
ures were performed on asymptomatic patients, in contrast
to countries with population based reimbursement, where
24% of all carotid procedures were done for asymptomatic
stenosis (p < .01) (Fig. 4). After using hierarchical analysis to
account for country and centre level clustering, fee for ser-
vice countries were more likely to perform procedures in
asymptomatic patients than population based reimburse-
ment countries (OR 5.8, 95% CI 4.4e7.7). Furthermore, in
countries with fee for service reimbursement, 37% of the
asymptomatic patients were older than 75 years compared
with 20% in population based reimbursement countries,
indicating a higher likelihood of treatment being offered to
this group (OR 2.7, 95% CI 1.4e5.2).n asymptomatic and symptomatic patients in the 10 participating
lyses because of the absence of carotid artery stenting reporting in
Figure 3. Variation between the hospitals in the proportion of carotid artery stenting for all carotid procedures (CAS vs. CEA). (A)
Asymptomatic. (B) Symptomatic. Note. New Zealand and Norway were excluded from the analyses because of the absence of CAS
reporting in the registry. CAS ¼ carotid artery stenting; CEA ¼ carotid endarterectomy.
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Figure 4. Treatment of asymptomatic stenosis and reimbursement
system.
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In symptomatic patients, the majority of patients were
treated by CEA (88%) and the minority of patients were
treated by CAS (12%). This percentage of CAS treatment
varied between 0% in Denmark and Iceland and 19% in the
United States (Fig. 2). Variation between centres was
highest in Australia (0e81%) and the United States (0e96%)
whereas in Denmark and Iceland CAS was not performed to
treat symptomatic patients (Fig. 3B). In Europe the variation
between the centres was highest in Hungary (0e29%), and
Sweden and Switzerland (0e15%).
Of all symptomatic patients, 19% were octogenarians;
the proportion was similar in CAS (18%) and CEA (19%)
patients. The variation between countries was higher
among CAS patients (0% in Norway to 29% in Switzerland)
than CEA patients (8% in Hungary to 25% in New Zealand)
(Supplementary Material Fig. S1).
Variation in the percentage of women treated for
symptomatic disease overall was high, with the percentage
of women lowest in Switzerland (29%) and Australia (30%)
and highest in the United States (38%) (Supplementary
Material Fig. S2).
CAS treatment of symptomatic versus asymptomatic
patients
There was considerable variation in the selection of patients
for CAS treatment in different countries. CAS was used
more frequently in the asymptomatic than in the symp-
tomatic cohort in Australia (p < .01), Hungary (p < 0.01),
Sweden (p < 0.01), and Switzerland (p ¼ .09) (Fig. 2). In
contrast, CAS was used more often to treat symptomatic
than asymptomatic patients in Finland (p < .40) and the
United States (p < .01). Denmark and Iceland did not utilise
CAS at all.
Trends over time
Overall, there was a 1.2% (from 10.5% to 9.3%, p ¼ .02)
decrease in the proportion of CAS utilised over time, with
this change occurring in both asymptomatic (from 12.2% to
10.7%, p ¼ .13) and symptomatic (from 9.4% to 8.4%,p ¼ .09) patients. The biggest decrease in asymptomatic
patients was seen in Australia, where the proportion of CAS
decreased from 15.5% to 11.9% (p ¼ .07) and in the United
States, from 11.3% to 7.9% (p < .01). The most remarkable
increase in the proportion of CAS in asymptomatic patients
was noted in Hungary (from 7.6% to 17.2%; p < .01). In
symptomatic patients the proportion of stenting decreased
in two countries: Australia (from 10.9% to 8.4%, p ¼ .02)
and Sweden (from 11.8% to 6.5%, p ¼ .06), and in other
countries there were no significant trends. The proportion
of CAS procedures among octogenarians varied between
9.0% and 9.6% over the time period studied, and did not
show a significant trend.DISCUSSION
The treatment of carotid stenosis is one of the best studied
disease processes in vascular surgery. Several societies have
published guidelines and recommendations about the in-
dications for CEA and CAS; however, there is considerable
variability among those recommendations.12 In an analysis
of 44 guidelines from 23 different regions/countries, the
recommendation for the treatment of asymptomatic severe
carotid stenosis varied from “CEA should be provided” to
“medical treatment alone.”12 Although based on the same
RCTs, the recommendations by the Society for Vascular
Surgery, the European Society for Vascular Surgery, the
American Heart Association, and the European Society for
Cardiology are not similar (Supplementary Material
Table S3). Perhaps not surprisingly, there exist large varia-
tions in the practice of CEA and CAS among the countries
and centres analysed in the current study. In this study,
which is the largest registry survey reported to date,
including 59,000 procedures from over 400 centres in the
United States, Europe, Australia, and New Zealand, the
biggest variation was seen in the treatment of patients with
asymptomatic carotid stenosis. Here, the percentage of
asymptomatic patients varied between 0 and 100% among
centres and between 0 and 60% among countries.
Furthermore, over 15% of the asymptomatic patients who
underwent CEA or CAS were 80 years or older, a population
that was excluded from most RCTs, and with sparse data to
support their treatment. In this registry, CAS remained
relatively uncommon in the treatment of carotid stenosis
during the 4 year period, and the proportion of stenting was
observed to decrease slightly in a few countries. This may
have been a consequence of the publication of short-term
results of the International Carotid Stenting Study (ICSS)
in 2010, where the risk of procedure related stroke of any
severity was higher following CAS than after CEA, and
where the authors concluded that, until long-term results
were available, CEA should remain the treatment of choice
for patients who were suitable candidates for surgery.15
Because of the inconsistency of the existing guidelines
and thus their failure to truly steer the clinical practice
patterns, deeper collaboration between the guideline
committees and consensus on the recommendations should
be achieved.
518 M. Venermo et al.The reason behind the variation in the proportion of
asymptomatic patients selected for carotid treatment in
different countries and centres is likely multifactorial. One
major reason could be related to the physician reimburse-
ment system in each country. In countries with fee for
service reimbursement many more asymptomatic patients
were treated than in countries with population based
reimbursement. This is in line with recent findings regarding
variations in management of abdominal aortic aneurysms in
countries participating in the ICVR, indicating that patients
are more likely to be treated at a lower diameter threshold
for an aneurysm in countries with a fee for service reim-
bursement system.16 Since treatment of asymptomatic pa-
tients is less beneficial, this suggests a more aggressive
approach motivated in part by reimbursement. With an
undercurrent of possible overtreatment and excessive
healthcare costs, the American Academy of Family Physi-
cians began a “Choosing Wisely” campaign to reduce
screening for carotid stenosis in asymptomatic patients,
which was in turn supported by the United States Preven-
tative Services Task Force statement recommending against
the routine screening for carotid artery stenosis in asymp-
tomatic patients.17 The impact of this recommendation will
need to be assessed in future studies. However, it may be
that these actions are insufficient and in the end the only
truly effective steering force would be the change in reim-
bursement system so that ineffective, or even potentially
harmful, procedures would not be reimbursed.
Within symptomatic patients, there was variation in the
utilisation of CAS among countries. In general, CEA was
preferred over CAS, but the proportion of patients under-
going CAS for symptomatic carotid stenosis varied from 0%
to 9%. Furthermore a relatively high proportion (19%) of
symptomatic patients treated were octogenarians, with a
high fraction (18%) undergoing CAS. In randomised trials
comparing CAS with CEA for symptomatic carotid stenosis,
CAS was associated with a higher risk of procedure related
stroke than CEA, particularly in elderly patients, but had
lower attendant risks of myocardial infarction, cranial nerve
palsy, and access site (vs. incision) haematomas.15,18e20 In a
separate analysis of ICSS patients who were randomised to
and received CAS, increasing age was an independent pre-
dictor of stroke, myocardial infarction, or death within 30
days of stenting, with a relative increase in risk of 17% for
every 5 years of increasing age. In contrast, the long-term
results of RCTs comparing CAS and CEA showed that the 5
and 10 year risk of stroke was low after either treatment in
both symptomatic and asymptomatic patients, with no
difference in restenosis rates.21,22 These conflicting data are
probably responsible for influencing these variations in
practice observed between centres and countries. Based on
similar efficacy long term, the utilisation of CAS may in-
crease in the future; however, this must be weighed against
the increased peri-procedural complications associated with
CAS in those of advanced age. Further study should be
dedicated to the appropriateness of CAS in the treatment of
patients  75 years of age, taking into account peri-
procedural risks, long-term outcomes and life expectancy.In this study, the proportion of asymptomatic patients in
the United States was significantly lower than that in earlier
reports, where over 90% of carotid artery interventions
were performed in asymptomatic patients based on claims
data.23,24 This is probably because the United States data in
this study were derived from the VQI, and this registry has a
more accurate representation of pre-operative symptoms
than is present in administrative claims data. The unreli-
ability of administrative data in determining symptom sta-
tus has been studied and reported previously.25,26 These
differences underscore the importance of using registry
data to accurately ascertain symptom status when evalu-
ating variations in practice and the appropriateness of
intervention for carotid stenosis.
This study has several limitations. First, different degrees of
validation are used in each country’s registry to assure that all
relevant procedures are included, but most have a high level
of capture within participating hospitals.27e31 Second, not all
registries include all hospitals or procedures performed in the
country, so this cannot be considered a population based
analysis. This especially affects the proportion of CAS pro-
cedures in some countries where CAS is performed by spe-
cialists who do not participate in these vascular registries.
Nonetheless, the variations observed are probably real and
not biased in a particular direction. Finally, details of patient
co-morbidities were not harmonized across the registries, so
these factors can only be compared in general context.
CONCLUSIONS
Despite significant evidence on treatment options for carotid
artery disease internationally, there is large variation in the
proportion of asymptomatic patients selected for CEA/CAS
among countries and centres participating in ICVR, which
may be influenced by reimbursement systems. The propor-
tion of CAS remained low during the study period in the
registries of all countries. Interestingly, the variation be-
tween centres was much higher than among countries in the
utilisation of CAS. Additional variation exists in the treat-
ment of women and octogenarians. Registry collaborations
spanning the globe such as ICVR can provide important data
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APPENDIX A. SUPPLEMENTARY DATA
Supplementary data related to this article can be found at
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